Skip to main content
. 2023 May 4;31(8):2507–2523. doi: 10.1016/j.ymthe.2023.04.022

Figure 1.

Figure 1

Chemotherapy-induced senescence leads to bone loss

(A) Schematic representation of the DoxoR-induced senescence model. At day 0, 15-week-old mice received either vehicle or DoxoR (10 mg/kg, intraperitoneal DoxoR). For an entire week, starting at days 7 and 21, mice received ABT263 (50 mg/kg, daily oral gavage) or vehicle 2. (B) qRT-PCR of senescence markers Cdkn1a, Cdkn2a, Il1α, Il6, and Csf2. RNA isolated from the tibiae and femurs of vehicle-, DoxoR-, ABT263-, and DoxoR + ABT263-treated mice. n = 4–6. (C) Quantitative parameters and 3D representation of cortical bone of tibiae measured by μ-CT. n = 6–10. (D) Quantitative parameters and 3D representation of the trabecular compartment of tibiae measured by μ-CT. n = 6–10. Data shown as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. One-way ANOVA.